Galatou Eleftheria, Mourelatou Elena, Hatziantoniou Sophia, Vizirianakis Ioannis S
Department of Life & Health Sciences, School of Sciences and Engineering, University of Nicosia, 2417 Nicosia, Cyprus.
Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece.
Antioxidants (Basel). 2022 May 27;11(6):1060. doi: 10.3390/antiox11061060.
Nonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic inflammation that characterizes NASH, which is highly correlated with atherosclerosis and coronary artery disease. Regarding drug therapy, research on the role of GLP-1 analogues and DPP4 inhibitors, novel classes of antidiabetic drugs, is growing. In this review, we outline the association between NASH and atherosclerosis, the underlying molecular mechanisms, and the effects of incretin-based drugs, especially GLP-1 RAs, for the therapeutic management of these conditions.
非酒精性脂肪性肝炎（NASH）是非酒精性脂肪性肝病（NAFLD）最严重的表现形式，NAFLD是2型糖尿病的常见并发症，可能导致肝硬化和肝细胞癌。氧化应激和肝细胞损伤是NASH特征性严重肝脏炎症的主要触发因素，NASH与动脉粥样硬化和冠状动脉疾病高度相关。关于药物治疗，新型抗糖尿病药物胰高血糖素样肽-1（GLP-1）类似物和二肽基肽酶4（DPP4）抑制剂作用的研究正在不断增加。在本综述中，我们概述了NASH与动脉粥样硬化之间的关联、潜在分子机制以及基于肠促胰素的药物，尤其是GLP-1受体激动剂（GLP-1 RAs）对这些病症治疗管理的作用。
